Serum Institute of India (SII) CEO Adar Poonawala said on Tuesday that about Rs 3,000 crore would be needed to increase the production capacity of the Covid-19 vaccine.
“We need roughly Rs 3,000 crore, which is not a small figure because we have already spent thousands of crores of rupees,” Poonawalla told a TV channel. We have to find other new ways to build our capacity.
He said that the company expects the production capacity of the Covishield vaccine to increase to 11 crore per month from June.
“We need roughly Rs 3,000 crore, which is not a small figure because we have already spent thousands of crores of rupees,” Poonawalla told news channel NDTV. We have to find other new ways to build our capacity. “
He said that the company expects the production capacity of the Covishield vaccine to increase to 11 crore per month from June.
Poonawala said that the company is producing 20 lakh doses per day.
“We have given more than 100 million doses in India alone and exported around 60 million doses to other countries,” he said.
The serum institute as well as other vaccine producers have also agreed with the government not to take profits.
He said that no other vaccine company in the world is providing vaccines at such reduced prices.
Poonawala said in another interview with ET Now that the Serum Institute is prioritizing India’s temporary needs over others.
Earlier Adar Poonawala announced that the second vaccine of Serum Institute is expected to be launched by September this year.
Adar Poonawala said, “The trial of Covaxin has finally started in India. This vaccine has been prepared through a partnership with Novavax and Serum Institute of India.
It has been tested against African and UK variants of Covid-19 and has an overall efficacy of 89 percent. Expected to be launched by September 2021 “
